Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Ajanta Pharma has informed that it enclosed the schedule of Analyst/Institutional Investor Meeting with the Company. The company has confirmed that the discussion during these meetings will be strictly on the basis of already published information.
The above information is a part of company’s filings submitted to BSE.